Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 134
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03099564 | Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | ||
| NCT03400254 | Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") | ||
| NCT01034631 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | ||
| NCT01485874 | Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | ||
| NCT03737123 | Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | ||
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | ||
| NCT00317200 | A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer | ||
| NCT03476174 | Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma | ||
| NCT02549209 | Pembro/Carbo/Taxol in Endometrial Cancer | ||
| NCT07471841 | Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax | ||
| NCT02581215 | Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer | ||
| NCT00216138 | Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck | ||
| NCT05467891 | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | ||
| NCT00216099 | Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer | ||
| NCT06809140 | Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | ||
| NCT07188896 | A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) | ||
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | ||
| NCT00235235 | A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer | ||
| NCT02581059 | Efficacy of Ginseng for Patients on Regorafenib | ||
| NCT04541173 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | ||
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | ||
| NCT00234494 | Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer | ||
| NCT02382406 | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | ||
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | ||
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | ||
| NCT02586610 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | ||
| NCT00216060 | Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy | ||
| NCT00732303 | Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer | ||
| NCT06863311 | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC | ||
| NCT03396471 | Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary | ||
| NCT00216112 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | ||
| NCT05903092 | MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer | ||
| NCT04470674 | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients | ||
| NCT03317158 | Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | ||
| NCT03558087 | Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing | ||
| NCT04364048 | Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer | ||
| NCT00216047 | PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer | ||
| NCT04886531 | Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | ||
| NCT00522665 | Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer | ||
| NCT01074970 | PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations | ||
| NCT02101385 | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | ||
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | ||
| NCT03451331 | Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer | ||
| NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | ||
| NCT07185945 | Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy | ||
| NCT06855225 | A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma | ||
| NCT02582749 | Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases | ||
| NCT00526799 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | ||
| NCT01681433 | OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | ||
| NCT00216203 | Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer |
